Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
32 studies found for:    "Encephalitis, Tick-Borne"
Show Display Options
RSS Create an RSS feed from your search for:
"Encephalitis, Tick-Borne"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting A Phase II, Open Label Trial of a Vaccine (FSME-IMMUN 0.5 mL Baxter) Against Tick-borne Encephalitis (TBE) for NIAID Workers Manipulating Tick Borne Encephalitis Virus (TBEV) in the Laboratory
Conditions: Tick-Borne Encephalitis;   Encephalitis, Tick-Borne;   Tick-Borne Disease;   Glycoprotein E, Flavivirus;   NSI Protein, Flavivirus
Intervention: Biological: FSME-IMMUN 0.5ml Baxter
2 Active, not recruiting Tick-Borne Encephalitis (TBE) Seropersistence After First Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401)
Condition: Encephalitis, Tick-Borne
Intervention: Biological: FSME-IMMUN 0.25 mL Junior (1.2 µg TBE antigen/0.25 mL) or FSME-IMMUN 0.5 mL (2.4µg TBE antigen/0.5 mL)
3 Completed An Extension Study to Determine the Persistence of Tick-borne Encephalitis (TBE)-Specific Antibody Responses Among Children and Adolescents Previously Immunized Against TBE
Condition: Tick Borne Encephalitis (TBE)
Intervention: Other: Serology blood draw
4 Completed Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults
Condition: Tick-Borne Encephalitis
Interventions: Biological: LGT(TP21)/DEN4;   Biological: Placebo
5 Completed TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209)
Condition: Encephalitis, Tick-Borne
Intervention: Biological: Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
6 Active, not recruiting Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules
Condition: Tick Borne Encephalitis
Intervention: Other: Blood Sampling
7 Active, not recruiting Cervicovaginal Immune Responses to 3 Deltoid or Thigh Intramuscular (IM) TicoVac
Condition: Tick-Borne Encephalitis
Intervention: Drug: TicoVac
8 Completed Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children
Condition: Encephalitis, Tick-Borne
Intervention: Biological: Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
9 Completed TBE Antibody Persistence and Booster Vaccination Study in Adults (Follow-up to Study 223)
Condition: Encephalitis, Tick-Borne
Intervention: Biological: Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
10 Unknown  Humoral Response to Tick-borne Encephalitis Vaccine in Elderly
Condition: Tick-borne Encephalitis
Intervention: Biological: FSME-immune
11 Completed Humoral and Cellular Immunity of Low and High-responders After Tick-borne Encephalitis Vaccination
Condition: Tick-borne Encephalitis
Intervention: Biological: TBE vaccination and influenza vaccination
12 Unknown  Evaluation of Immunogenicity of Different Tick Borne Encephalitis (TBE) Fast Protective Traveler Schemes With Inactivated TBE Whole Virus Vaccine
Condition: Tick Borne Encephalitis
Intervention: Biological: FSME vaccination (FSME-Immun)
13 Completed Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225)
Condition: Encephalitis, Tick-Borne
Intervention: Biological: Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl
14 Completed Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children
Condition: Encephalitis, Tick-Borne
Intervention: Biological: Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl
15 Completed Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years
Condition: Encephalitis, Tick-Borne
Intervention: Biological: Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
16 Completed Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 Years
Condition: Encephalitis, Tick-Borne
Intervention: Biological: Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
17 Completed FSME IMMUN NEW Follow-Up to Study 208 in Volunteers Aged 16 to 66 Years
Condition: Encephalitis, Tick-Borne
Intervention: Biological: Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
18 Recruiting Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients
Condition: Tick Borne Encephalitis
Intervention: Biological: TBE virus vaccine
19 Active, not recruiting TBE Seropersistence up to 10 Years After First Booster in Adults
Condition: Tick-borne Encephalitis (TBE)
Intervention: Biological: FSME-IMMUN 0.5 ml
20 Completed Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization Schedule
Condition: Encephalitis, Tick-Borne
Intervention: Biological: Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl

   Previous Page Studies Shown (1-20) Next Page (21-32) Show next page of results    Last Page
Indicates status has not been verified in more than two years